Baidu
map

RET突变型甲状腺髓样癌:selpercatinib的III期临床试验已开始

2019-12-31 Allan MedSci原创

礼来公司近日宣布,selpercatinib(也称为LOXO-292)治疗RET突变型甲状腺髓样癌(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。

礼来公司近日宣布,selpercatinib(也称为LOXO-292)治疗RET突变型甲状腺髓样癌(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinibIII临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。

马萨诸塞州总医院头颈癌中心主任Lori Wirth说:大约60%的甲状腺髓样癌患者具有激活的RET点突变,但目前的治疗方法对许多患者而言并不理想。甲状腺髓样癌发病主要原因是RET原癌基因突变,当出现单侧或双侧甲状腺肿块、呼吸不畅、吞咽困难、声音嘶哑、手足抽搐、类癌综合征等症状应警惕甲状腺髓样癌的发生。


原始出处:

https://www.firstwordpharma.com/node/1690348?tsid=4

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>(也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>)治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16120, encryptionId=376e16120ab, topicName=Selpercatinib), TopicDto(id=104797, encryptionId=bfac104e9710, topicName=LOXO-292), TopicDto(id=104798, encryptionId=a624104e98a8, topicName=RET突变), TopicDto(id=69924, encryptionId=f4d069924e7, topicName=甲状腺髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:40:50 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 07 23:39:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu May 07 19:39:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041393, encodeId=3a3e20413939d, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 24 12:39:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974500, encodeId=37c619e45003b, content=<a href='/topic/show?id=6bf0153924b' target=_blank style='color:#2F92EE;'>#RET突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15392, encryptionId=6bf0153924b, topicName=RET突变型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Thu Jul 16 13:39:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Aug 14 23:39:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 12 22:39:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822005, encodeId=dfc91822005df, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Oct 23 19:39:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728252, encodeId=3bc11e282526b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 25 20:39:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916216, encodeId=8c7e19162160c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jan 20 02:39:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2022-09-20 小小医者

    #Selpercatinib#(也称为#LOXO-292#)治疗#RET突变##甲状腺髓样癌#(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>(也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>)治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16120, encryptionId=376e16120ab, topicName=Selpercatinib), TopicDto(id=104797, encryptionId=bfac104e9710, topicName=LOXO-292), TopicDto(id=104798, encryptionId=a624104e98a8, topicName=RET突变), TopicDto(id=69924, encryptionId=f4d069924e7, topicName=甲状腺髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:40:50 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 07 23:39:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu May 07 19:39:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041393, encodeId=3a3e20413939d, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 24 12:39:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974500, encodeId=37c619e45003b, content=<a href='/topic/show?id=6bf0153924b' target=_blank style='color:#2F92EE;'>#RET突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15392, encryptionId=6bf0153924b, topicName=RET突变型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Thu Jul 16 13:39:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Aug 14 23:39:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 12 22:39:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822005, encodeId=dfc91822005df, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Oct 23 19:39:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728252, encodeId=3bc11e282526b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 25 20:39:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916216, encodeId=8c7e19162160c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jan 20 02:39:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>(也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>)治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16120, encryptionId=376e16120ab, topicName=Selpercatinib), TopicDto(id=104797, encryptionId=bfac104e9710, topicName=LOXO-292), TopicDto(id=104798, encryptionId=a624104e98a8, topicName=RET突变), TopicDto(id=69924, encryptionId=f4d069924e7, topicName=甲状腺髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:40:50 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 07 23:39:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu May 07 19:39:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041393, encodeId=3a3e20413939d, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 24 12:39:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974500, encodeId=37c619e45003b, content=<a href='/topic/show?id=6bf0153924b' target=_blank style='color:#2F92EE;'>#RET突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15392, encryptionId=6bf0153924b, topicName=RET突变型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Thu Jul 16 13:39:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Aug 14 23:39:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 12 22:39:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822005, encodeId=dfc91822005df, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Oct 23 19:39:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728252, encodeId=3bc11e282526b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 25 20:39:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916216, encodeId=8c7e19162160c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jan 20 02:39:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2020-05-07 ysjykql
  4. [GetPortalCommentsPageByObjectIdResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>(也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>)治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16120, encryptionId=376e16120ab, topicName=Selpercatinib), TopicDto(id=104797, encryptionId=bfac104e9710, topicName=LOXO-292), TopicDto(id=104798, encryptionId=a624104e98a8, topicName=RET突变), TopicDto(id=69924, encryptionId=f4d069924e7, topicName=甲状腺髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:40:50 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 07 23:39:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu May 07 19:39:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041393, encodeId=3a3e20413939d, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 24 12:39:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974500, encodeId=37c619e45003b, content=<a href='/topic/show?id=6bf0153924b' target=_blank style='color:#2F92EE;'>#RET突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15392, encryptionId=6bf0153924b, topicName=RET突变型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Thu Jul 16 13:39:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Aug 14 23:39:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 12 22:39:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822005, encodeId=dfc91822005df, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Oct 23 19:39:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728252, encodeId=3bc11e282526b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 25 20:39:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916216, encodeId=8c7e19162160c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jan 20 02:39:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>(也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>)治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16120, encryptionId=376e16120ab, topicName=Selpercatinib), TopicDto(id=104797, encryptionId=bfac104e9710, topicName=LOXO-292), TopicDto(id=104798, encryptionId=a624104e98a8, topicName=RET突变), TopicDto(id=69924, encryptionId=f4d069924e7, topicName=甲状腺髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:40:50 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 07 23:39:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu May 07 19:39:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041393, encodeId=3a3e20413939d, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 24 12:39:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974500, encodeId=37c619e45003b, content=<a href='/topic/show?id=6bf0153924b' target=_blank style='color:#2F92EE;'>#RET突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15392, encryptionId=6bf0153924b, topicName=RET突变型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Thu Jul 16 13:39:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Aug 14 23:39:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 12 22:39:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822005, encodeId=dfc91822005df, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Oct 23 19:39:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728252, encodeId=3bc11e282526b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 25 20:39:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916216, encodeId=8c7e19162160c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jan 20 02:39:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>(也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>)治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16120, encryptionId=376e16120ab, topicName=Selpercatinib), TopicDto(id=104797, encryptionId=bfac104e9710, topicName=LOXO-292), TopicDto(id=104798, encryptionId=a624104e98a8, topicName=RET突变), TopicDto(id=69924, encryptionId=f4d069924e7, topicName=甲状腺髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:40:50 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 07 23:39:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu May 07 19:39:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041393, encodeId=3a3e20413939d, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 24 12:39:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974500, encodeId=37c619e45003b, content=<a href='/topic/show?id=6bf0153924b' target=_blank style='color:#2F92EE;'>#RET突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15392, encryptionId=6bf0153924b, topicName=RET突变型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Thu Jul 16 13:39:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Aug 14 23:39:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 12 22:39:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822005, encodeId=dfc91822005df, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Oct 23 19:39:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728252, encodeId=3bc11e282526b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 25 20:39:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916216, encodeId=8c7e19162160c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jan 20 02:39:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>(也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>)治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16120, encryptionId=376e16120ab, topicName=Selpercatinib), TopicDto(id=104797, encryptionId=bfac104e9710, topicName=LOXO-292), TopicDto(id=104798, encryptionId=a624104e98a8, topicName=RET突变), TopicDto(id=69924, encryptionId=f4d069924e7, topicName=甲状腺髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:40:50 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 07 23:39:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu May 07 19:39:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041393, encodeId=3a3e20413939d, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 24 12:39:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974500, encodeId=37c619e45003b, content=<a href='/topic/show?id=6bf0153924b' target=_blank style='color:#2F92EE;'>#RET突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15392, encryptionId=6bf0153924b, topicName=RET突变型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Thu Jul 16 13:39:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Aug 14 23:39:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 12 22:39:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822005, encodeId=dfc91822005df, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Oct 23 19:39:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728252, encodeId=3bc11e282526b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 25 20:39:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916216, encodeId=8c7e19162160c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jan 20 02:39:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>(也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>)治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16120, encryptionId=376e16120ab, topicName=Selpercatinib), TopicDto(id=104797, encryptionId=bfac104e9710, topicName=LOXO-292), TopicDto(id=104798, encryptionId=a624104e98a8, topicName=RET突变), TopicDto(id=69924, encryptionId=f4d069924e7, topicName=甲状腺髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:40:50 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 07 23:39:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu May 07 19:39:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041393, encodeId=3a3e20413939d, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 24 12:39:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974500, encodeId=37c619e45003b, content=<a href='/topic/show?id=6bf0153924b' target=_blank style='color:#2F92EE;'>#RET突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15392, encryptionId=6bf0153924b, topicName=RET突变型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Thu Jul 16 13:39:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Aug 14 23:39:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 12 22:39:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822005, encodeId=dfc91822005df, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Oct 23 19:39:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728252, encodeId=3bc11e282526b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 25 20:39:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916216, encodeId=8c7e19162160c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jan 20 02:39:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2020-10-23 Boyinsh
  9. [GetPortalCommentsPageByObjectIdResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>(也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>)治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16120, encryptionId=376e16120ab, topicName=Selpercatinib), TopicDto(id=104797, encryptionId=bfac104e9710, topicName=LOXO-292), TopicDto(id=104798, encryptionId=a624104e98a8, topicName=RET突变), TopicDto(id=69924, encryptionId=f4d069924e7, topicName=甲状腺髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:40:50 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 07 23:39:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu May 07 19:39:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041393, encodeId=3a3e20413939d, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 24 12:39:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974500, encodeId=37c619e45003b, content=<a href='/topic/show?id=6bf0153924b' target=_blank style='color:#2F92EE;'>#RET突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15392, encryptionId=6bf0153924b, topicName=RET突变型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Thu Jul 16 13:39:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Aug 14 23:39:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 12 22:39:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822005, encodeId=dfc91822005df, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Oct 23 19:39:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728252, encodeId=3bc11e282526b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 25 20:39:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916216, encodeId=8c7e19162160c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jan 20 02:39:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2020-05-25 feather89
  10. [GetPortalCommentsPageByObjectIdResponse(id=2089218, encodeId=f7f22089218fd, content=<a href='/topic/show?id=376e16120ab' target=_blank style='color:#2F92EE;'>#Selpercatinib#</a>(也称为<a href='/topic/show?id=bfac104e9710' target=_blank style='color:#2F92EE;'>#LOXO-292#</a>)治疗<a href='/topic/show?id=a624104e98a8' target=_blank style='color:#2F92EE;'>#RET突变#</a>型<a href='/topic/show?id=f4d069924e7' target=_blank style='color:#2F92EE;'>#甲状腺髓样癌#</a>(MTC)的LIBRETTO-531临床试验(NCT04211337)已开始。这是第二项针对selpercatinib的III期临床试验。入组患者将被随机分配接受selpercatinib或医生选择的疗法。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16120, encryptionId=376e16120ab, topicName=Selpercatinib), TopicDto(id=104797, encryptionId=bfac104e9710, topicName=LOXO-292), TopicDto(id=104798, encryptionId=a624104e98a8, topicName=RET突变), TopicDto(id=69924, encryptionId=f4d069924e7, topicName=甲状腺髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:40:50 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652973, encodeId=2f8516529e3b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 07 23:39:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu May 07 19:39:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041393, encodeId=3a3e20413939d, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 24 12:39:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974500, encodeId=37c619e45003b, content=<a href='/topic/show?id=6bf0153924b' target=_blank style='color:#2F92EE;'>#RET突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15392, encryptionId=6bf0153924b, topicName=RET突变型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Thu Jul 16 13:39:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088777, encodeId=913a2088e77ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Aug 14 23:39:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 12 22:39:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822005, encodeId=dfc91822005df, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Oct 23 19:39:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728252, encodeId=3bc11e282526b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 25 20:39:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916216, encodeId=8c7e19162160c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Jan 20 02:39:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2020-01-20 juliusluan78

相关资讯

高明教授:RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望

甲状腺癌是最为常见的内分泌恶性肿瘤,近年来发病率逐年上升。根据肿瘤起源及分化差异,甲状腺癌可以分为多种亚型,包括甲状腺乳头状癌、甲状腺滤泡癌、甲状腺髓样癌以及甲状腺未分化癌等。其中甲状腺髓样癌约占甲状腺癌的2%~4%,病变来源于甲状腺滤泡旁细胞,是预后较差,早期易发生转移的亚型。

Baidu
map
Baidu
map
Baidu
map